Provided by Tiger Trade Technology Pte. Ltd.

Travere Therapeutics, Inc.

56.93
+0.08000.14%
Post-market: 56.930.00000.00%19:30 EDT
Volume:1.72M
Turnover:97.82M
Market Cap:5.37B
PE:-119.49
High:57.53
Open:57.21
Low:56.34
Close:56.85
52wk High:68.73
52wk Low:22.59
Shares:94.26M
Float Shares:92.77M
Volume Ratio:1.08
T/O Rate:1.86%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4764
EPS(LYR):-0.2864
ROE:-236.35%
ROA:-3.73%
PB:218.84
PE(LYR):-198.81

Loading ...

Travere Therapeutics Q1 product sales rise on FILSPARI demand

Reuters
·
May 05

Travere Q1 FY26 net loss narrows to $37.1 million; net product sales climb 64.1% to $124.5 million

Reuters
·
May 05

BRIEF-Travere Therapeutics Q1 EPS USD -0.4

Reuters
·
May 05

Travere Therapeutics Q1 Operating Income USD -36.915 Million

THOMSON REUTERS
·
May 05

Press Release: Travere Therapeutics Reports First Quarter 2026 Financial Results

Dow Jones
·
May 05

Travere Therapeutics Inc expected to post a loss of 26 cents a share - Earnings Preview

Reuters
·
May 02

Travere Therapeutics (TVTX) Gets a Buy from Guggenheim

TIPRANKS
·
Apr 29

Press Release: Travere Therapeutics to Report First Quarter 2026 Financial Results

Dow Jones
·
Apr 28

Travere Therapeutics to report quarterly results, host conference call

Reuters
·
Apr 28

A Look At Travere Therapeutics (TVTX) Valuation After FILSPARI’s Expanded FDA Approval In FSGS

Simply Wall St.
·
Apr 25

Travere Therapeutics Inc : Jefferies Raises Target Price to $50 From $42

THOMSON REUTERS
·
Apr 24

Travere Therapeutics (TVTX) Receives a Buy from Piper Sandler

TIPRANKS
·
Apr 24

A Look At Travere Therapeutics (TVTX) Valuation After FDA Expands FILSPARI Approval For FSGS

Simply Wall St.
·
Apr 18

Travere Therapeutics (TVTX) Gets a Buy from Evercore ISI

TIPRANKS
·
Apr 17

Travere director Gary Lyons disposes of common shares worth $328,560

Reuters
·
Apr 17

Travere director Roy D. Baynes disposes of 32,750 shares worth $1,345,155

Reuters
·
Apr 17

Travere Therapeutics CAO Sandra Calvin disposes of common shares worth $902,565.39

Reuters
·
Apr 17

BRIEF-FDA Approves Treatment For Patients With Focal Segmental Glomerulosclerosis

Reuters
·
Apr 17

FDA: Approved Treatment for Patients With Focal Segmental Glomerulosclerosis

THOMSON REUTERS
·
Apr 17

Travere CLO Elizabeth Reed disposes of USD 2.1 million common shares

Reuters
·
Apr 16